Sotalol

John Alvin Kpaeyeh Jr; John Marcus Wharton

doi:10.1016/j.ccep.2016.02.007

Sotalol

Card Electrophysiol Clin. 2016 Jun;8(2):437-52. doi: 10.1016/j.ccep.2016.02.007.

Authors

John Alvin Kpaeyeh Jr¹, John Marcus Wharton²

Affiliations

¹ Division of Cardiology, Department of Medicine, Tourville Arrhythmia Center, Medical University of South Carolina, 114 Doughty Street, MSC 592, Charleston, SC 29425-5920, USA.
² Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Tourville Arrhythmia Center, Medical University of South Carolina, 114 Doughty Street, BM 216, MSC 592, Charleston, SC 29425-5920, USA. Electronic address: whartonj@musc.edu.

PMID: 27261833
DOI: 10.1016/j.ccep.2016.02.007

Abstract

Sotalol is effective for treating atrial fibrillation (AF), ventricular tachycardia, premature ventricular contractions, and supraventricular tachycardia. Racemic (DL) sotalol inhibits the rapid component of the delayed rectifier potassium current. There is a near linear relationship between sotalol dosage and QT interval prolongation. However, in dose ranging trials in patients with AF, low-dose sotalol was not more effective than placebo. Orally administered sotalol has a bioavailability of nearly 100%. The only significant drug interactions are the need to avoid or limit use of concomitant drugs that cause QT prolongation, bradycardia, and/or hypotension.

Keywords: Atrial fibrillation; Long QT syndrome; Potassium channel blocker; Sotalol; Ventricular tachycardia.

Publication types

Review

MeSH terms

Action Potentials / drug effects
Anti-Arrhythmia Agents*
Arrhythmias, Cardiac / drug therapy
Humans
Sotalol*

Substances

Anti-Arrhythmia Agents
Sotalol